ABSTRACT GP catalyzes the phosphorylation of glycogen to Glc-1-P. Because of its fundamental role in the metabolism of glycogen, GP has been the target for a systematic structure-assisted design of inhibitory compounds, which could be of value in the therapeutic treatment of type 2 diabetes melli-tus. The most potent catalytic-site inhibitor of GP identified to date is spirohydantoin of glucopyr-anose (hydan). In this work, we employ MD free energy simulations to calculate the relative binding affinities for GP of hydan and two spirohydantoin analogues, methyl-hydan and n-hydan, in which a hydrogen atom is replaced by a methyl- or amino group, respectively. The results are compared with the experimental relative affinities of these ligands
Glycogen phosphorylase is a molecular target for the design of potential hypoglycemic agents. Struct...
Design of inhibitors of glycogen phosphorylase (GP) with pharmaceutical applications in improving gl...
Glycogen phosphorylase (GP) is an important therapeutic target for type 2 diabetes having a direct i...
GP catalyzes the phosphorylation of glycogen to Glc-1-P. Because of its fundamental role in the meta...
Glycogen phosphorylase (GP) is currently exploited as a target for inhibition of hepatic glycogenoly...
Glycogen phosphorylase (GP) is currently exploited as a target for inhibition of hepatic glycogenoly...
A glucopyranose spirohydantoin (a pyranose analogue of the potent herbicide, hydantocidin) has been ...
Glycogen phosphorylase (GP), a validated target for the development of anti-hyperglycaemic agents, h...
Glycogen phosphorylase (GP), a validated target for the development of anti-hyperglycaemic agents, h...
Several inhibitors of the large regulatory enzyme glycogen phosphorylase (GP) have been studied in c...
Several inhibitors of the large regulatory enzyme glycogen phosphorylase (GP) have been studied in c...
Several inhibitors of the large regulatory enzyme glycogen phosphorylase (GP) have been studied in c...
The synthesis of two epimeric spirohydantoins of glucopyranose provides the first examples of pyrano...
Glycogen phosphorylase is a molecular target for the design of potential hypoglycemic agents. Struct...
Design of inhibitors of glycogen phosphorylase (GP) with pharmaceutical applications in improving gl...
Glycogen phosphorylase is a molecular target for the design of potential hypoglycemic agents. Struct...
Design of inhibitors of glycogen phosphorylase (GP) with pharmaceutical applications in improving gl...
Glycogen phosphorylase (GP) is an important therapeutic target for type 2 diabetes having a direct i...
GP catalyzes the phosphorylation of glycogen to Glc-1-P. Because of its fundamental role in the meta...
Glycogen phosphorylase (GP) is currently exploited as a target for inhibition of hepatic glycogenoly...
Glycogen phosphorylase (GP) is currently exploited as a target for inhibition of hepatic glycogenoly...
A glucopyranose spirohydantoin (a pyranose analogue of the potent herbicide, hydantocidin) has been ...
Glycogen phosphorylase (GP), a validated target for the development of anti-hyperglycaemic agents, h...
Glycogen phosphorylase (GP), a validated target for the development of anti-hyperglycaemic agents, h...
Several inhibitors of the large regulatory enzyme glycogen phosphorylase (GP) have been studied in c...
Several inhibitors of the large regulatory enzyme glycogen phosphorylase (GP) have been studied in c...
Several inhibitors of the large regulatory enzyme glycogen phosphorylase (GP) have been studied in c...
The synthesis of two epimeric spirohydantoins of glucopyranose provides the first examples of pyrano...
Glycogen phosphorylase is a molecular target for the design of potential hypoglycemic agents. Struct...
Design of inhibitors of glycogen phosphorylase (GP) with pharmaceutical applications in improving gl...
Glycogen phosphorylase is a molecular target for the design of potential hypoglycemic agents. Struct...
Design of inhibitors of glycogen phosphorylase (GP) with pharmaceutical applications in improving gl...
Glycogen phosphorylase (GP) is an important therapeutic target for type 2 diabetes having a direct i...